Motion Sickness

Pharma

Vanda tests motion sickness drug Nereus in GLP-1 patients

Vanda is kicking off a phase 3 trial to evaluate the ability of its motion sickness drug Nereus to prevent vomiting in those taking a GLP-1 treatment.

Kevin Dunleavy Apr 9, 2026 2:56pm

Vanda, Agios score holiday season FDA approvals

Jan 2, 2026 11:33am

FDA rejects Defender's motion sickness nasal gel candidate

Jan 30, 2024 5:00pm